Dawn L Hershman

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi Getting a grip on aromatase inhibitor-associated arthralgias
    Dawn L Hershman
    J Clin Oncol 26:3120-1. 2008
  2. ncbi Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors
    Dawn L Hershman
    Department of Medicine, The Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, 161 Fort Washington Avenue, 10 1068, New York, NY, 10032, USA
    Breast Cancer Res Treat 138:795-806. 2013
  3. ncbi Comparative effectiveness research in oncology methodology: observational data
    Dawn L Hershman
    Columbia University Medical Center and the Herbert Irving Comprehensive Cancer Center, New York, NY, USA
    J Clin Oncol 30:4215-22. 2012
  4. ncbi Influence of health insurance, hospital factors and physician volume on receipt of immediate post-mastectomy reconstruction in women with invasive and non-invasive breast cancer
    D L Hershman
    Department of Medicine, Columbia University College of Physicians and Surgeons, Columbia University Medical Center, 161 Fort Washington Avenue, 10 1068, New York, NY 10032, USA
    Breast Cancer Res Treat 136:535-45. 2012
  5. ncbi Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer
    Dawn L Hershman
    Columbia University and New York Presbyterian Hospital, New York, NY 10032, USA
    J Clin Oncol 30:806-12. 2012
  6. ncbi Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer
    Dawn L Hershman
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 100:199-206. 2008
  7. ncbi Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer
    Katherine D Crew
    Columbia University, 161 Fort Washington Ave, 10 1068, New York, NY 10032, USA
    J Clin Oncol 28:1154-60. 2010
  8. ncbi Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy
    Dawn Hershman
    Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 99:196-205. 2007
  9. ncbi Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients
    Dawn L Hershman
    Mailman School of Public Health, Columbia University Medical Center, 161 Fort Washington Ave, New York, NY 10032, USA
    J Clin Oncol 28:4120-8. 2010
  10. ncbi Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival
    Dawn L Hershman
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, New York, NY 10032, USA
    Int J Radiat Oncol Biol Phys 65:1353-60. 2006

Detail Information

Publications101 found, 100 shown here

  1. ncbi Getting a grip on aromatase inhibitor-associated arthralgias
    Dawn L Hershman
    J Clin Oncol 26:3120-1. 2008
  2. ncbi Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors
    Dawn L Hershman
    Department of Medicine, The Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, 161 Fort Washington Avenue, 10 1068, New York, NY, 10032, USA
    Breast Cancer Res Treat 138:795-806. 2013
    ..Future interventions should determine the most efficient and effective method for delivering survivorship care plans...
  3. ncbi Comparative effectiveness research in oncology methodology: observational data
    Dawn L Hershman
    Columbia University Medical Center and the Herbert Irving Comprehensive Cancer Center, New York, NY, USA
    J Clin Oncol 30:4215-22. 2012
    ....
  4. ncbi Influence of health insurance, hospital factors and physician volume on receipt of immediate post-mastectomy reconstruction in women with invasive and non-invasive breast cancer
    D L Hershman
    Department of Medicine, Columbia University College of Physicians and Surgeons, Columbia University Medical Center, 161 Fort Washington Avenue, 10 1068, New York, NY 10032, USA
    Breast Cancer Res Treat 136:535-45. 2012
    ..Public policy should ensure that access to reconstructive surgery is universally available...
  5. ncbi Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer
    Dawn L Hershman
    Columbia University and New York Presbyterian Hospital, New York, NY 10032, USA
    J Clin Oncol 30:806-12. 2012
    ..We examined first-cycle colony-stimulating factor use (FC-CSF) before and after 2002 and estimated US expenditures for dose-dense chemotherapy...
  6. ncbi Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer
    Dawn L Hershman
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 100:199-206. 2008
    ..We investigated the association of surgeon-related factors with receipt of adjuvant radiotherapy after BCS...
  7. ncbi Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer
    Katherine D Crew
    Columbia University, 161 Fort Washington Ave, 10 1068, New York, NY 10032, USA
    J Clin Oncol 28:1154-60. 2010
    ..Acupuncture is an effective and well-tolerated strategy for managing this common treatment-related side effect...
  8. ncbi Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy
    Dawn Hershman
    Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 99:196-205. 2007
    ..Although these growth factors support chemotherapy, their long-term safety has not been evaluated. We studied the association between G-CSF use and incidence of leukemia in a population-based sample of breast cancer patients...
  9. ncbi Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients
    Dawn L Hershman
    Mailman School of Public Health, Columbia University Medical Center, 161 Fort Washington Ave, New York, NY 10032, USA
    J Clin Oncol 28:4120-8. 2010
    ..We investigated the rates and predictors of early discontinuation and nonadherence to hormonal therapy in patients enrolled in Kaiser Permanente of Northern California health system...
  10. ncbi Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival
    Dawn L Hershman
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, New York, NY 10032, USA
    Int J Radiat Oncol Biol Phys 65:1353-60. 2006
    ..We investigated factors that influence the time interval between lumpectomy and RT, and the association between that interval and survival...
  11. ncbi Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
    Dawn L Hershman
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University Medical Center, 161 Fort Washington Avenue, 10 1068, New York, NY 10032, USA
    Breast Cancer Res Treat 126:529-37. 2011
    ..Both early discontinuation and non-adherence to HT were common and associated with increased mortality. Interventions to improve continuation of and adherence to HT may be critical to improve BC survival...
  12. ncbi Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer
    Dawn Hershman
    Department of Medicine, Mailman School of Public Health, Columbia University, New York, New York, USA
    Cancer 107:2581-8. 2006
    ..However, to the authors' knowledge, the effect of the interval between surgery and the initiation of chemotherapy on survival has not been investigated...
  13. ncbi Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy
    Dawn L Hershman
    Department of Medicine, College of Physicians and Surgeons, New York, NY, USA
    Breast Cancer Res Treat 125:767-74. 2011
    ..The FACT/GOG-Ntx is an appropriate outcome measure for clinical trials evaluating ways to prevent long-term neurotoxicity in BC survivors...
  14. ncbi Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment
    Dawn L Hershman
    M S, Columbia University, 161 Fort Washington Avenue, 10 1068, New York, New York 10032, USA
    J Clin Endocrinol Metab 95:559-66. 2010
    ..BMD remained stable 1 yr after completion of ZA. Serum CTX increased significantly by 12 and 24 months. More frequent administration may be required to suppress bone resorption in this patient population...
  15. ncbi Racial disparities in treatment and survival among women with early-stage breast cancer
    Dawn Hershman
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, New York, NY, USA
    J Clin Oncol 23:6639-46. 2005
    ..We analyzed the association of race and survival with duration of treatment and number of treatment cycles among women receiving chemotherapy for early-stage breast cancer...
  16. ncbi Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer
    Dawn L Hershman
    Columbia University Medical Center, 161 Fort Washington Ave, 10 1068, New York, NY 10032, USA
    J Natl Cancer Inst 101:1633-41. 2009
    ..Erythropoiesis-stimulating agents (erythropoietin and darbepoietin) have been approved to reduce the number of blood transfusions required during chemotherapy; however, concerns about the risks of venous thromboembolism and mortality exist...
  17. ncbi Management of complications from estrogen deprivation in breast cancer patients
    Dawn L Hershman
    Department of Medicine and Epidemiology, College of Physicians and Surgeons and the Mailman School of Public Health, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY 10032, USA
    Curr Oncol Rep 11:29-36. 2009
    ....
  18. ncbi Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer
    Dawn Hershman
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    J Natl Cancer Inst 95:1545-8. 2003
    ....
  19. ncbi Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: a population-based study
    Dawn Hershman
    The Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, New York, NY 10032, USA
    Gynecol Oncol 92:293-9. 2004
    ..The purpose of this study was to assess the patterns of use of chemotherapy in women with stage II ovarian cancer, and to compare the survival of treated and untreated patients aged 65+ years in a population-based sample...
  20. ncbi Surgeon characteristics and use of breast conservation surgery in women with early stage breast cancer
    Dawn L Hershman
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York Presbyterian Hospital, New York, New York 10032, USA
    Ann Surg 249:828-33. 2009
    ..Aside from clinical factors, this decision may be associated with surgeon and patient characteristics. We investigated the effect of surgeon characteristics on the BCS rate...
  21. ncbi Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer
    Dawn Hershman
    Herbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington, Room 1068, New York, NY 10032, USA
    Curr Oncol Rep 6:277-84. 2004
    ..This review summarizes the prevention and management of osteoporosis and osteopenia resulting from cancer treatment in survivors of breast and prostate cancer...
  22. ncbi Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer
    Dawn Hershman
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, 161 Fort Washington, New York, NY 10032, USA
    Gynecol Oncol 94:540-9. 2004
    ..We previously showed that only about half of women over the age of 65 years with this disease received platinum-based chemotherapy, and that the likelihood of receiving it decreases with age...
  23. ncbi Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer
    Dawn L Hershman
    Department of Medicine, Herbert Irving Comprehensive Cancer Center, College of Physicians andSurgeons, Columbia University, New York, NY 10032, USA
    J Clin Oncol 26:4739-45. 2008
    ..We examined whether zoledronic acid (ZA) prevents bone loss in premenopausal women receiving chemotherapy for early-stage BC...
  24. ncbi Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women
    Dawn L Hershman
    Herbert Irving Comprehensive Cancer Center, Columbia Presbyterian Hospital University, New York, NY, USA
    Cancer 115:3848-57. 2009
    ..In the current study, the association between oncologist characteristics and the receipt of chemotherapy in elderly women with BC was evaluated...
  25. ncbi Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma
    Dawn L Hershman
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    J Clin Oncol 26:3159-65. 2008
    ..We studied the cardiac effects of doxorubicin in a population-based sample of older patients with diffuse large B-cell lymphoma (DLBCL)...
  26. ncbi Impact of primary prophylaxis on febrile neutropenia within community practices in the US
    Dawn Hershman
    Columbia University, Department of Medicine Oncology, New York, NY 10032, USA
    J Med Econ 12:203-10. 2009
    ..To determine if granulocyte-colony-stimulating factor (G-CSF) primary prophylaxis is associated with a lower risk of febrile neutropenia (FN) than non-primary prophylaxis...
  27. ncbi Racial disparities in treatment and survival of male breast cancer
    Katherine D Crew
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Clin Oncol 25:1089-98. 2007
    ..We analyzed race and other predictors of treatment and survival among men with stage I-III breast cancer...
  28. ncbi Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer
    Jason D Wright
    Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, Mailman School of Public Health, and The Herbert Irving Comprehensive Cancer Center, New York, New York 10032, USA
    Obstet Gynecol 120:871-81. 2012
    ..Cytoreductive surgery is associated with extensive morbidity and may delay chemotherapy. We examined the associations among cytoreduction, perioperative complications, and delay or omission of chemotherapy...
  29. ncbi Duration of adjuvant chemotherapy for colon cancer and survival among the elderly
    Alfred I Neugut
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, New York, NY 10032, USA
    J Clin Oncol 24:2368-75. 2006
    ..However, little is known about the predictors of, or the survival associated with, duration of chemotherapy in the community...
  30. ncbi Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group
    Kathy S Albain
    Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA
    J Natl Cancer Inst 101:984-92. 2009
    ..Our objective was to determine whether racial disparities in survival exist among patients enrolled in consecutive trials conducted by the Southwest Oncology Group (SWOG)...
  31. ncbi Noninitiation of adjuvant chemotherapy in women with localized breast cancer: the breast cancer quality of care study
    Alfred I Neugut
    Division of Medical Oncology, Columbia University Medical Center, 722 W 168th St, Room 725, New York, NY 10032, USA
    J Clin Oncol 30:3800-9. 2012
    ..For some women, adjuvant chemotherapy for nonmetastatic breast cancer decreases recurrences and increases survival; however, patient-physician decisions regarding chemotherapy receipt can be influenced by medical and nonmedical factors...
  32. ncbi Access to conservative surgical therapy for adolescents with benign ovarian masses
    Sloane Berger-Chen
    Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York, USA
    Obstet Gynecol 119:270-5. 2012
    ..To perform a population-based analysis to determine possible factors associated with use of laparoscopy and ovarian-conserving cystectomy...
  33. ncbi Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer
    Jason D Wright
    Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    J Clin Oncol 30:783-91. 2012
    ..We performed a population-based analysis to compare laparoscopic hysterectomy and robotic hysterectomy for endometrial cancer...
  34. ncbi Prognostic significance of adenocarcinoma histology in women with cervical cancer
    Vijaya Galic
    Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, 161 Fort Washington Ave, 8th Floor, New York, NY 10032, United States
    Gynecol Oncol 125:287-91. 2012
    ..We performed a population-based analysis to determine the effect of histology on survival for women with invasive cervical cancer...
  35. ncbi Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study
    John J Doyle
    Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, 161 Ft Washington, Rm 1068, New York, NY 10032, USA
    J Clin Oncol 23:8597-605. 2005
    ..As the number of long-term survivors grows, identifying and minimizing the late effects of treatment will become increasingly important...
  36. ncbi Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women
    Dawn L Hershman
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons Columbia University, 161 Ft Washington Room 1068, New York, NY 10032, USA
    Breast Cancer Res Treat 99:313-21. 2006
    ..Whether this reflects the medical impact of the delay of chemotherapy or factors associated with delay is unclear, but until this is clarified, patients should be encouraged to initiate treatment without significant delay...
  37. ncbi Feasibility and economic impact of same-day discharge for women who undergo laparoscopic hysterectomy
    Maria B Schiavone
    Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Am J Obstet Gynecol 207:382.e1-9. 2012
    ..We examined the use, safety, and economic impact of same-day discharge for women undergoing laparoscopic hysterectomy...
  38. ncbi Failure to rescue as a source of variation in hospital mortality for ovarian cancer
    Jason D Wright
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, 161 Fort Washington Ave, 8th Floor, New York, NY 10032, USA
    J Clin Oncol 30:3976-82. 2012
    ..We examined the role of complications, failure to rescue from complications, and mortality based on hospital volume for ovarian cancer...
  39. ncbi Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease
    Jason D Wright
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, 161 Fort Washington Ave, Eighth Floor, New York, NY 10032, USA
    JAMA 309:689-98. 2013
    ....
  40. ncbi Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL)
    Alfred I Neugut
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Breast Cancer Res Treat 134:419-28. 2012
    ..Educational interventions to women about the benefits of hormonal therapy may decrease negative beliefs and increase hormone therapy initiation...
  41. ncbi Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation
    Abby B Siegel
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Transplantation 94:539-43. 2012
    ..For many cancers, features of the metabolic syndrome, such as diabetes and obesity, have been associated with both increased risk of cancer development and poor outcomes...
  42. ncbi Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer
    Jason D Wright
    Columbia University, New York, NY, USA
    J Clin Oncol 29:3408-18. 2011
    ..However, once approved, these treatments are often used differently than as tested in trials. We performed an analysis to determine the patterns of use of erythropoiesis-stimulating agents (ESAs)...
  43. ncbi Duffy (Fy), DARC, and neutropenia among women from the United States, Europe and the Caribbean
    Victor R Grann
    Departments of Medicine, Epidemiology, and Health Policy, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
    Br J Haematol 143:288-93. 2008
    ..A better understanding of these associations may help to improve cancer outcomes among individuals of African ancestry...
  44. ncbi Defining the limits of radical cytoreductive surgery for ovarian cancer
    Jason D Wright
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, USA
    Gynecol Oncol 123:467-73. 2011
    ..We examined the outcomes of cytoreductive surgery to determine if there are groups of patients in which the morbidity is so substantial that alternate treatment strategies are warranted...
  45. ncbi Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients
    Katherine D Crew
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    J Cancer Surviv 1:283-91. 2007
    ..However, patients receiving AIs may experience joint symptoms, which may lead to early discontinuation of this effective therapy. We hypothesize that acupuncture is a safe and effective treatment for AI-induced arthralgias...
  46. ncbi Prevalence and predictors of antioxidant supplement use during breast cancer treatment: the Long Island Breast Cancer Study Project
    Heather Greenlee
    Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA
    Cancer 115:3271-82. 2009
    ..The authors of this report analyzed the prevalence of and factors associated with antioxidant supplement use during breast cancer (BC) treatment among women who participated in the Long Island Breast Cancer Study Project...
  47. ncbi Association between plasma 25-hydroxyvitamin D and breast cancer risk
    Katherine D Crew
    Department of Medicine, Division of Hematology Oncology, Columbia University, New York, New York 10032, USA
    Cancer Prev Res (Phila) 2:598-604. 2009
    ..Well-designed clinical trials are urgently needed to determine whether vitamin D supplementation is effective for breast cancer chemoprevention...
  48. ncbi Comparative effectiveness of minimally invasive and abdominal radical hysterectomy for cervical cancer
    Jason D Wright
    Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Gynecol Oncol 127:11-7. 2012
    ..We analyzed the uptake, morbidity, and cost of laparoscopic and robotic radical hysterectomies for cervical cancer...
  49. ncbi Effect of surgical volume on outcomes for laparoscopic hysterectomy for benign indications
    Michelle R Wallenstein
    Department of Obstetrics, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Obstet Gynecol 119:709-16. 2012
    ..To estimate the influence of surgical volume on outcome and resource utilization for laparoscopic hysterectomy for benign indications...
  50. ncbi Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma
    Jeanette C Yu
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Cancer 116:1801-9. 2010
    ..The authors investigated factors associated with the receipt of liver transplant among patients with HCC and evaluated the effects of these differences on survival...
  51. ncbi Influence of surgical volume on outcome for laparoscopic hysterectomy for endometrial cancer
    Jason D Wright
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Ann Surg Oncol 19:948-58. 2012
    ..We examined the influence of surgeon and hospital case volume on morbidity, mortality, and resource utilization for women with endometrial cancer undergoing laparoscopic hysterectomy...
  52. ncbi The Breast Cancer Quality of Care Study (BQUAL): a multi-center study to determine causes for noncompliance with breast cancer adjuvant therapy
    Alfred I Neugut
    Department of Medicine, and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, School of Public Health, Columbia University Medical Center, 722 W 168th Street, New York, NY 10032, USA
    Breast J 18:203-13. 2012
    ..This information may be useful in planning interventions to improve quality of care...
  53. ncbi Prevention of bone loss after withdrawal of tamoxifen
    Adi Cohen
    Department of Medicine, Division of Endocrinology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Endocr Pract 14:162-7. 2008
    ..The objective of this study was to assess, in a randomized, double-blind, placebo-controlled trial, whether administration of alendronate (70 mg weekly) would prevent bone loss associated with tamoxifen discontinuation...
  54. ncbi Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer
    Alfred I Neugut
    Herbert Irving Comprehensive Cancer Center, College of Physiciansand Surgeons, Columbia University, New York, NY, USA
    J Clin Oncol 29:2534-42. 2011
    ..Noncompliance with adjuvant hormonal therapy among women with breast cancer is common. Little is known about the impact of financial factors, such as co-payments, on noncompliance...
  55. ncbi Ethnicity and persistent symptom burden in breast cancer survivors
    Olivia S Fu
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    J Cancer Surviv 3:241-50. 2009
    ..Relatively few studies of breast cancer survivors have included nonwhite women or women who do not speak English...
  56. ncbi Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly
    Julian A Abrams
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
    Cancer 115:4924-33. 2009
    ..The authors of this report compared outcomes of esophagectomy versus chemoradiation in a population-based sample of elderly patients with early stage esophageal cancer...
  57. ncbi Use of adjuvant 5-fluorouracil and radiation therapy after gastric cancer resection among the elderly and impact on survival
    Joshua Strauss
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Int J Radiat Oncol Biol Phys 76:1404-12. 2010
    ..We investigated the effectiveness of adjuvant chemoRT after gastric cancer resection in an elderly general population and its effects by stage...
  58. ncbi High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy
    Katherine D Crew
    Department of Medicine, Division of Oncology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    J Clin Oncol 27:2151-6. 2009
    ....
  59. ncbi Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study
    Vijaya Sundararajan
    Department of Epidemiology, Joseph L. Mailman School of Public Health, College of Physicians and Surgeons, New York University, 630 W 168th St, New York, NY 10032, USA
    J Clin Oncol 20:173-8. 2002
    ..Further research is needed to elucidate to what degree this represents appropriate clinical judgment and to what degree other factors, such as patient choice, play a role...
  60. ncbi Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer
    Heather Greenlee
    Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA
    Support Care Cancer 21:1077-87. 2013
    ..Many women with hormone receptor-positive breast cancer discontinue effective aromatase inhibitor (AI) treatment due to joint symptoms...
  61. ncbi Interpersonal influences and attitudes about adjuvant therapy treatment decisions among non-metastatic breast cancer patients: an examination of differences by age and race/ethnicity in the BQUAL study
    Rachel C Shelton
    Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA
    Breast Cancer Res Treat 137:817-28. 2013
    ....
  62. ncbi The commercialization of robotic surgery: unsubstantiated marketing of gynecologic surgery by hospitals
    Maria B Schiavone
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Am J Obstet Gynecol 207:174.e1-7. 2012
    ..We analyzed the content, quality, and accuracy of information provided on hospital web sites about robotic gynecologic surgery...
  63. ncbi Patterns of care and treatment outcomes for elderly women with cervical cancer
    Charu Sharma
    Department of Radiation Oncology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Cancer 118:3618-26. 2012
    ..Cervical cancer is common in the elderly. The authors examined the patterns of care, treatment, and outcomes of elderly women with cervical cancer...
  64. ncbi Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer
    Katherine D Crew
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Clin Oncol 25:3877-83. 2007
    ..The purpose of the current study was to evaluate the prevalence of and identify risk factors for AI-related joint symptoms...
  65. ncbi Impact of socioeconomic status on extent of lymph node dissection for colon cancer
    Russell B McBride
    Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York 10032, USA
    Cancer Epidemiol Biomarkers Prev 19:738-45. 2010
    ..We investigated whether this new standard of care was differentially adopted across racial and socioeconomic lines...
  66. ncbi Obesity and microvascular invasion in hepatocellular carcinoma
    Abby B Siegel
    Department of Medicine, Columbia University, New York, New York 10032, USA
    Cancer Invest 28:1063-9. 2010
    ..We hypothesized that hepatocellular carcinoma (HCC) patients with higher Body Mass Index (BMI) might have more microvascular invasion (MVI) in their tumors...
  67. ncbi Within-stage racial differences in tumor size and number of positive lymph nodes in women with breast cancer
    Russell McBride
    Department of Epidemiology, Mailman School of Public Health, New York, New York, USA
    Cancer 110:1201-8. 2007
    ..It was hypothesized that differences in the tumor size and number of positive lymph nodes within each disease stage contribute to the survival disparity...
  68. ncbi Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer
    Elizabeth L Kaufman
    Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
    J Clin Oncol 26:392-8. 2008
    ..Prior studies have found that postmastectomy radiotherapy (PMRT) for breast cancer (BC) increases the risk of lung cancer (LC). We explored the joint effects of cigarette smoking and PMRT on LC risk...
  69. ncbi Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897
    Dawn L Hershman
    Columbia University, New York, NY, USA
    J Clin Oncol 27:2157-62. 2009
    ..We assessed the association between race and treatment discontinuation/delay, WBC counts, and survival in women enrolled onto breast cancer clinical trials...
  70. ncbi Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis
    Victor R Grann
    Herbert Irving Comprehensive Cancer Center, Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 W 168th Street, New York, NY 10032, USA
    J Clin Oncol 20:2520-9. 2002
    ..Observational studies and clinical trials are needed to verify the results of this analysis of the long-term benefits of preventive strategies among BRCA1/2-positive women...
  71. ncbi Breast biopsy and race/ethnicity among women without breast cancer
    Judith S Jacobson
    Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
    Cancer Detect Prev 30:129-33. 2006
    ..Our findings may also be relevant to the well-known association of breast cancer stage at diagnosis with low income and minority race/ethnicity...
  72. ncbi Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers
    Victor R Grann
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
    Breast Cancer Res Treat 125:837-47. 2011
    ..Annual screening with MRI and mammography was the most effective strategy because it was associated with the longest quality-adjusted survival, but it was also very expensive...
  73. ncbi Neutropenia in 6 ethnic groups from the Caribbean and the U.S
    Victor R Grann
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York City, New York 10032, USA
    Cancer 113:854-60. 2008
    ....
  74. ncbi Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer
    Jennifer C Livaudais
    Department of Health Evidence and Policy, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    Breast Cancer Res Treat 131:607-17. 2012
    ..Findings need to be confirmed in other insured populations and the reasons for under-initiation among these groups need to be explored...
  75. ncbi Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)
    Lara E Sucheston
    Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Breast Cancer Res Treat 130:993-1002. 2011
    ..If replicated, women with these genotypes should be closely monitored for toxicities and could be targeted for preventive measures or alternative therapeutic approaches...
  76. ncbi Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002
    Abby B Siegel
    Department of Medicine, Mailman School of Public Health, Columbia University, New York, New York, USA
    Am J Gastroenterol 103:120-7. 2008
    ..We assessed recent predictors of use of liver transplantation and its effect on survival for those with nonmetastatic HCC...
  77. ncbi Use of antioxidant supplements during breast cancer treatment: a comprehensive review
    Heather Greenlee
    Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th St, 7th Floor, New York, NY 10032, USA
    Breast Cancer Res Treat 115:437-52. 2009
    ..We conducted a comprehensive review of literature on the associations between antioxidant supplement use during breast cancer treatment and patient outcomes...
  78. ncbi Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation
    Kristin Anderson
    Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Joseph L. Mailman School of Public Health, Columbia University, and New York Presbyterian Hospital, New York, New York 10032, USA
    Ann Intern Med 144:397-406. 2006
    ..CONCLUSION: On the basis of this model, the most cost-effective strategies for BRCA mutation carriers, with and without quality adjustment, were oophorectomy alone and oophorectomy and mastectomy, respectively...
  79. ncbi Treatment of hot flushes in breast and prostate cancer
    Kerin B Adelson
    Department of Medicine, The Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Expert Opin Pharmacother 6:1095-106. 2005
    ..The most promising agents act on the CNS and include selective serotonin reuptake inhibitors, as well as venlafaxine and gabapentin...
  80. ncbi The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study
    FELICE A TAGER
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University Medical Center, 1150 St Nicholas Ave, Suite 1 121, New York, NY, USA
    Breast Cancer Res Treat 123:25-34. 2010
    ..Future studies should control for the independent effects of slowed motor functioning when looking to study possible chemotherapy related cognitive processing deficits...
  81. ncbi Long natural history of recurrent granulosa cell tumor of the ovary 23 years after initial diagnosis: a case report and review of the literature
    Katherine D Crew
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10027, USA
    Gynecol Oncol 96:235-40. 2005
    ..CONCLUSION: This case illustrates the benefits of cytoreductive surgery for the management of recurrent disease, the use of serum tumor markers to help guide therapy, and the importance of extended follow-up...
  82. ncbi The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme
    Rose Lai
    Department of Neurology, The Neurological Institute, Columbia University, 710 West 168th Street, Room 204, New York, NY 10032, USA
    Neuro Oncol 12:190-8. 2010
    ..Although effort should be made to initiate radiotherapy as soon as possible after surgical resection/biopsy, a brief delay similar to that experienced by our cohort does not have a significant impact on survival...
  83. ncbi Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma
    Victor R Grann
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Cancer 107:1530-41. 2006
    ..In the past 25 years, clinical trials have demonstrated the benefits of chemotherapy for patients with aggressive non-Hodgkin lymphoma. The authors analyzed the predictors and outcomes of chemotherapy among elderly patients with lymphoma...
  84. ncbi Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma
    Victor R Grann
    Division of Medical Oncology, Department of Medicine, Columbia University Medical Center, New York, New York 10032, USA
    Cancer 103:2241-51. 2005
    ..The objective of this study was to assess hormone receptor status as an independent predictor of survival in a population-based cohort of women with breast carcinoma who were followed for up to 11 years...
  85. ncbi Barriers to minority participation in breast carcinoma prevention trials
    Victor R Grann
    Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York 10032, USA
    Cancer 104:374-9. 2005
    ..Less than 4% of participants in the previously conducted P1 (tamoxifen vs. placebo) trial were minority women. We, therefore, studied barriers to minority participation in STAR among black, white, and Hispanic women who completed an RAF...
  86. ncbi Regional and racial disparities in breast cancer-specific mortality
    Victor Grann
    Department of Medicine, Columbia University, New York, NY 10021, USA
    Soc Sci Med 62:337-47. 2006
    ....
  87. ncbi The risk of hepatocellular carcinoma in patients with previous malignancy
    Abby B Siegel
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10033, USA
    Cancer Invest 26:511-5. 2008
  88. ncbi Treatment for breast cancer in patients with Alzheimer's disease
    Sherri Sheinfeld Gorin
    Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA
    J Am Geriatr Soc 53:1897-904. 2005
    ..To report use of breast cancer treatment (surgery, radiation, and chemotherapy) by patients with Alzheimer's disease (AD)...
  89. ncbi Breast cancer-related preferences among women with and without BRCA mutations
    Victor R Grann
    Herbert Irving Comprehensive Cancer Center, Department of Medicine, and Joseph L Mailman School of Public Health, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Breast Cancer Res Treat 119:177-84. 2010
    ..Our findings support the use of average-risk individuals' time trade-off preference ratings for health care policy development...
  90. ncbi Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy
    Bo Yu
    Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, New York 10032, USA
    Cancer 116:2099-105. 2010
    ..The objective of the current study was to assess levels of mullerian inhibitory substance (MIS), estradiol (E2), follicle-stimulating hormone (FSH), and menstrual status, in women undergoing chemotherapy...
  91. ncbi Quality of perioperative venous thromboembolism prophylaxis in gynecologic surgery
    Jason D Wright
    Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Obstet Gynecol 118:978-86. 2011
    ..To estimate the use of venous thromboembolism prophylaxis in women undergoing gynecologic surgery and to estimate the patient, physician, and hospital characteristics associated with guideline-based prophylaxis...
  92. ncbi Anthracycline cardiotoxicity after breast cancer treatment
    Dawn L Hershman
    Columbia University, New York, N Y 10032, USA
    Oncology (Williston Park) 23:227-34. 2009
    ..Finally, we review monitoring and preventive practices that may reduce the long-term risk of anthracycline-related cardiotoxicity...
  93. ncbi Radiation therapy, cardiac risk factors, and cardiac toxicity in early-stage breast cancer patients
    John J Doyle
    Department of Epidemiology, Mailman School of Public, College of Physicians and Surgeons, Columbia University, New York Presbyterian Hospital, New York, NY, USA
    Int J Radiat Oncol Biol Phys 68:82-93. 2007
    ..We studied the cardiac effects of RT and the impact of pre-existing cardiac risk factors (CRFs) in a population-based sample of older patients with breast cancer...
  94. ncbi Digital optical tomography system for dynamic breast imaging
    Molly L Flexman
    Columbia University, Department of Biomedical Engineering, 351 Engineering Terrace, 1210 Amsterdam Avenue, New York, New York 10027, USA
    J Biomed Opt 16:076014. 2011
    ..Included is a preliminary study of one healthy patient and two breast cancer patients showing the ability to identify an invasive carcinoma based on the hemodynamic response to a breath hold...
  95. ncbi Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma
    Amy D Tiersten
    Department of Medicine, Columbia Presbyterian Medical Center, New York, NY 10032, USA
    Gynecol Oncol 92:635-8. 2004
    ..This trial investigated the safety and efficacy of paclitaxel and topotecan combination chemotherapy for patients with advanced cervical cancer (ACC)...
  96. ncbi Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy
    Clare Taylor
    Department of Microbiology, College of Physicians and Surgeons, Columbia University, New York, NY 10027 6902, USA
    Clin Cancer Res 13:5133-43. 2007
    ..We have assessed whether immune sensitization to the HER-2/neu tumor antigen occurs during treatment with the anti-HER-2/neu monoclonal antibody trastuzumab...
  97. ncbi Traumatic stress symptoms and breast cancer: the role of childhood abuse
    Rachel E Goldsmith
    Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY, USA
    Child Abuse Negl 34:465-70. 2010
    ..The present study investigated relations between reported childhood abuse and recent traumatic stress symptoms in women newly diagnosed with breast cancer (n=330)...
  98. ncbi Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis
    Dawn Hershman
    Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Joseph L. Mailman School of Public Health, Columbia University, 630 West 168th St, New York, NY 10032, USA
    J Clin Oncol 20:9-16. 2002
    ..For women with a very high risk of invasive breast cancer, chemoprevention with tamoxifen seems to be cost-effective...
  99. ncbi Anthracycline cardiotoxicity: one size does not fit all!
    Dawn L Hershman
    J Natl Cancer Inst 100:1046-7. 2008
  100. ncbi Common psychosocial factors underlying breast cancer screening and breast cancer treatment adherence: a conceptual review and synthesis
    Carol Magai
    Department of Psychology, Long Island University, Brooklyn, New York 11201, USA
    J Womens Health (Larchmt) 16:11-23. 2007
    ....
  101. ncbi Cancer chemoprevention: how do we know what works?
    Alfred I Neugut
    J Clin Oncol 25:1461-2. 2007

Research Grants4

  1. Determinants and risks of use and overuse of expensive oncology drugs
    Dawn Hershman; Fiscal Year: 2009
    ..We propose to use the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database to evaluate several important new costly therapies for their patterns of "appropriate use", "over-use", benefits and toxicities ..
  2. Osteoporosis Prevention in Early Stage Breast Cancer
    Dawn Hershman; Fiscal Year: 2006
    ..abstract_text> ..
  3. Determinants and risks of use and overuse of expensive oncology drugs
    Dawn Hershman; Fiscal Year: 2010
    ..We propose to use the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database to evaluate several important new costly therapies for their patterns of "appropriate use", "over-use", benefits and toxicities ..